05/03/2023 1
PURINERGIC RECEPTOR
PRESENTED BY
Sandhya Talla
M.PHARM (FIRST YEAR)
DEPARTMENT OF PHARMACOLOGY
CONTENT
• History & Introduction• ATP as neurotransmitter• Synthesis, store, release and metabolism of ATP• Types of purinergic receptor• Distribution of purinergic receptors• Structure of purinergic receptor• Purinergic signalling• Role of purinergic receptor• Therapeutic potential• Recent trends
2
3
The transmitter substance release
from Non-cholinergic & Non-
adrenergic nerves of Gut may be
ATP or some related purine
nucleotide.
These nerves has been termed as
“Purinergic nerves”
Geoffrey Burnstock(1972)
(Molecular M.N.,2008)
HISTORY
(Ghosh,2008)
INTRODUCTION
What is purinergic receptors?
The purinergic system involves the purine nucleotides, ATP , ADP, and the
nucleoside, adenosine
Purinergic nerves are located on Aurbach’s plexus.
4
5
Aurbach’s plexus is a collection of nerve fibre and that are mainly found in the muscle tissue of human intestine . These plexus are mainly responsible for generating peristalsis movement.
AURBACH’S PLEXUS:-
The substance must be released from terminal axon when nerves are activated.
ATP is contained in synaptic vesicles of both adrenergic and cholinergic
neurons, and it works as an energy currency.
ATP is released on nerve stimulation in a Ca2+-dependent fashion
6
ATP as a Neurotransmitter ( burnstock,2006 )
7
ATP
ADP
AMP
Adenosine
Inosine
ATpase
Adenosine deaminase
Adenosine uptake
P2 purinoreceptor
AdenosineLarge opaque vesicleContaining ATP
SMOOTH MUSCLE
Synthesis, storege, release and metabolism of ATP ( burnstock,2014)
.
8
P1 P2
A1 A2 A3 P2X P2Y
Purinergic receptor
Types of Purinergic Receptors (Burnstock et al ,2012 )
P2Y1,P2Y2,P2Y4,P2Y6P2X1,P2X2,P2X3,P2X4
05/03/2023
Receptors Main distribution
A1 Brain, spinal cord,testis,heart.
A2 Brain, Heart,spleen, lungs.
A3 Lung,Liver, Brain, Testis.
9
Receptors Main distribution
P2X1 Smooth muscle, cerebellum, platelets
P2X2 Smooth muscle, sensory, gangalia
P2X3 Sympathetic neuronsP2X4 CNS, testis,colon
Receptors Main distributionP2 Y1 Epithelial cell,Endothelial cell,
P2Y2 Immun cell, osteoblast,kidney tubules
P2Y4 Endothelial cell
P2Y6 Placenta,T cell,thymus
Distribution of purinergic receptors (Burnstock et al, 2012)
P1 receptor:- (G- protien couple receptors)
7-Transmembrane(TM) domains of
hydrophobic amino acid---constitute
an α-helix of ~21–28 amino acids
10
Structure of Purine Receptor (Burnstock et.,al 2012)
P2x receptor :- ( Ligand gated ion channel)
Large extracellular loop, with 10 conserved
cysteine residues forming a series of disulfide
bridges.
11
Structure of Purine Receptor
P2y receptor :-( G- protien couple receptor)
Some TM-spanning regions, particularly
TM3, TM6 & TM7 and structural diversity
of intracellular NH2 & COOH terminus
among P2Y sub-Types
12
Structure of Purine Receptor
Short term neuronal signalling-
secretion
vasodilation
Co-transmission
Long term neuronal signalling
Cell proliferation
Cell differentiation
Inflammation
13
Purinergic Signall ing (Burnstock,2014l)
14
Co-transmission (Burnstock,2014)
15
Cell proliferation and differentiation (Burnstock, 2014)
1) In Central Nervous System
2) In Respiratory System
3) In Cardiovascular System
4) In Gastrointestinal Tract
5) In endocrine system
6) In Urinary system
16
Role of purinergic receptor
Release of excitatory neurotransmitter (GABA,glycine)
Release of inhibitory neurotransmitter (glutamate)
Anticonvulsant effects
17
Central nervous System (Burnstock,2008)
Purine increases mucus secretion from goblets cells.
Purinergic activation causes bronchoconstriction.
18
Respiratory system
19
Cardiac system (Burnstock,2003)
Slows AV nodal conduction (negative dromotropy)
Decrease heart rate (negative chronotrophy)
Decrease atrial contractality (negative contraction)
Inhibits pacemaker
20
It causes
Relaxation of stomach.
Decreases peristalsis movement.
P2x3 receptor present on gut wall produces pain sensation
21
Gastrointestinal Tract
(Fernando, et al 2014)
Purinergic signaling causes contraction of urinary bladder.
Purinoceptor involved in regulation of renin secretion,
glomerular filtration and transport of water, ions, nutrients.
P2x3 responsible for micturation reflux and pain
22
Urinary System
ATP stimulate release of insulin
ATP modulate aldosterone production
ATP inhibit secretion of estradiol and progesterone from ovary
Inhibit lipolysis
23
Endocrine Glands
1) Parkinson’s disease :-
Adenosine A2a receptor antagonists are mainly used.
2) Epilepsy :-
Adenosine by activation of A1 receptors in hippocampus exerts
predominant inhibitory effects.
These inhibitory actions of adenosine can be used therapeutically
to suppress seizures.24
Therapeutic Potential
( Burnstock,et al 2003)
3) Ischaemia :-
Adenosine used as a cytoprotective agent during myocardial ischaemia
i) improved tissue perfusion
ii) anti-inflammatory action
25
Therapeutic Potential
(Burnstock, et,al 2003)
Atherosclerosis:-
Adenosine and ATP have a number of cardiovascular protective effect in addition of vasodilation ,including promotion of the endothelial and smooth muscle cell proliferation and increased in the expression of vascular endothelial grawth factor (VEGF).
26
Therapeutic Potential
(Burnstock,2003)
• Purinergic signalling in ovary
• Acupuncture : a Novel hypothesis for involvment of purinergic signalling
27
Recent Trends
ATP produced inside the cell can be released into the extracellular area in different ways.
purinergic activity in ovary – including sensitivity of gonadotropin in several ovarian cells types, i.e Granulosa cell , theca cell.
role of ATP as an important intraovarian messenger and regulate the ovarian function.
28
Purinergic signalling in ovary
(Molecular Reproduction and development,2015)
29
Purinergic signalling in ovary
30
Acupuncture: A novel hypothesis for the involvement of purinergic signalling
( Burnstock,2009)
31
References
Molecular inervention ,M.N Ghosh; purinergic Nerves, 2004 M.N Ghosh purinergic receptors fundamental of experiments Annualreviews;structural and chemical organisation of Aurbach plexus. Geoffrey Burnstock (2006);Historical review: ATP as a neurotransmitter Geoffrey burnstock (2006 ); historical review : ATP as a neurotransmitter Geoffrey Burnstock (2012) purinergic signaling in healthy and diseased skin ;volume 132 Geoffrey Burnstock (2012);purinergic signaling in healthy and diseased skin Geoffrey Burnstock (2012);purinergic signaling in healthy and diseased skin Geoffrey Burnstock (2014);purinergic signaling;from discovery to current development Geoffrey Burnstock (2014);purinergic signaling ;from discovery to current development Geoffrey Burnstock (2008) ;purinergic signaling and disorder of CNS Geoffrey burnstock 2003;involvment of purinergic signaling in cardiovascular diseased fernando.ochoa-corts (2014) potential for developing purinergic drug for GIT disesead Geoffrey Burnstock;(2008) ;purinergic signaling and disorder of CNS Geoffrey Burnstock (2003); Involvment of purinergic signaling in cardiovascular diseased Angelica s (2015);purinergic signaling In overy molecular Reproduction and development Geoffrey Burnstock (2009)Acupuncture: A novel hypothesis for the involment purinergic signaling
32